Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
VNDA's Cash-to-Debt is ranked higher than
93% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. VNDA: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
VNDA' s Cash-to-Debt Range Over the Past 10 Years
Min: 44.31  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.62
VNDA's Equity-to-Asset is ranked lower than
56% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. VNDA: 0.62 )
Ranked among companies with meaningful Equity-to-Asset only.
VNDA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.07  Med: 0.31 Max: 0.94
Current: 0.62
0.07
0.94
Interest Coverage No Debt
VNDA's Interest Coverage is ranked higher than
90% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. VNDA: No Debt )
Ranked among companies with meaningful Interest Coverage only.
VNDA' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 6
Altman Z-Score: 3.53
Beneish M-Score: -2.58
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -12.72
VNDA's Operating Margin % is ranked higher than
65% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. VNDA: -12.72 )
Ranked among companies with meaningful Operating Margin % only.
VNDA' s Operating Margin % Range Over the Past 10 Years
Min: -790.41  Med: -35.4 Max: 40
Current: -12.72
-790.41
40
Net Margin % -12.33
VNDA's Net Margin % is ranked higher than
66% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. VNDA: -12.33 )
Ranked among companies with meaningful Net Margin % only.
VNDA' s Net Margin % Range Over the Past 10 Years
Min: -788.46  Med: -33.81 Max: 40.25
Current: -12.33
-788.46
40.25
ROE % -14.11
VNDA's ROE % is ranked higher than
65% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. VNDA: -14.11 )
Ranked among companies with meaningful ROE % only.
VNDA' s ROE % Range Over the Past 10 Years
Min: -134.08  Med: -52.74 Max: 23.67
Current: -14.11
-134.08
23.67
ROA % -8.65
VNDA's ROA % is ranked higher than
68% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. VNDA: -8.65 )
Ranked among companies with meaningful ROA % only.
VNDA' s ROA % Range Over the Past 10 Years
Min: -111.28  Med: -16.55 Max: 12.81
Current: -8.65
-111.28
12.81
ROC (Joel Greenblatt) % -405.25
VNDA's ROC (Joel Greenblatt) % is ranked higher than
50% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. VNDA: -405.25 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
VNDA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4620.09  Med: -1029.58 Max: 784.55
Current: -405.25
-4620.09
784.55
3-Year Revenue Growth Rate 44.40
VNDA's 3-Year Revenue Growth Rate is ranked higher than
85% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. VNDA: 44.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
VNDA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -1.85 Max: 90.4
Current: 44.4
0
90.4
3-Year EBITDA Growth Rate -37.60
VNDA's 3-Year EBITDA Growth Rate is ranked lower than
87% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. VNDA: -37.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
VNDA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -31.3 Max: 22.5
Current: -37.6
0
22.5
3-Year EPS without NRI Growth Rate -15.90
VNDA's 3-Year EPS without NRI Growth Rate is ranked lower than
68% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. VNDA: -15.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
VNDA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -30.5 Max: -2.4
Current: -15.9
GuruFocus has detected 2 Warning Signs with Vanda Pharmaceuticals Inc $VNDA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» VNDA's 10-Y Financials

Financials (Next Earnings Date: 2017-05-02)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

VNDA Guru Trades in Q1 2016

Jim Simons 416,900 sh (+23.57%)
Paul Tudor Jones Sold Out
John Paulson 3,927,000 sh (-0.49%)
» More
Q2 2016

VNDA Guru Trades in Q2 2016

Paul Tudor Jones 12,719 sh (New)
Joel Greenblatt 14,304 sh (New)
John Paulson 3,864,717 sh (-1.59%)
Jim Simons 151,050 sh (-63.77%)
» More
Q3 2016

VNDA Guru Trades in Q3 2016

Steven Cohen 542,700 sh (New)
Paul Tudor Jones 48,953 sh (+284.88%)
Jim Simons 432,050 sh (+186.03%)
Joel Greenblatt 27,244 sh (+90.46%)
John Paulson 2,175,000 sh (-43.72%)
» More
Q4 2016

VNDA Guru Trades in Q4 2016

Joel Greenblatt 60,217 sh (+121.03%)
Jim Simons 568,350 sh (+31.55%)
Paul Tudor Jones 50,547 sh (+3.26%)
John Paulson Sold Out
Steven Cohen 151,100 sh (-72.16%)
» More
» Details

Insider Trades

Latest Guru Trades with VNDA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ANIK, NAS:WVE, OTCPK:GNIIF, NAS:CTMX, NAS:MGNX, NAS:RVNC, NAS:OMER, NAS:PGNX, NAS:KERX, OTCPK:IPHYF, NAS:BCRX, NAS:AMRI, OTCPK:MEOBF, NAS:ARDX, NAS:ATRA, NAS:IMMU, NAS:ACIU, NAS:ENTA, NAS:RGNX, OTCPK:PHMMF » details
Traded in other countries:VM4.Germany,
Headquarter Location:USA
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of products for the treatment of central nervous system disorders. Its products include HETLIOZ, Fanapt, Trichostatin A, AQW051, and VLY-686.

Vanda Pharmaceuticals focuses on the development and commercialization of therapies for central nervous system disorders. Its key drug, Hetlioz, is an oral compound approved for the orphan indication of non-24-hour sleep-wake disorder. Vanda also developed Fanapt, which is approved for the treatment of schizophrenia. All of the firm's therapies were in-licensed from Big Pharma.

Ratios

vs
industry
vs
history
PB Ratio 4.84
VNDA's PB Ratio is ranked lower than
59% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. VNDA: 4.84 )
Ranked among companies with meaningful PB Ratio only.
VNDA' s PB Ratio Range Over the Past 10 Years
Min: 2.53  Med: 5.63 Max: 623.46
Current: 4.84
2.53
623.46
PS Ratio 4.29
VNDA's PS Ratio is ranked higher than
74% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. VNDA: 4.29 )
Ranked among companies with meaningful PS Ratio only.
VNDA' s PS Ratio Range Over the Past 10 Years
Min: 2.63  Med: 5.84 Max: 69.88
Current: 4.29
2.63
69.88
EV-to-EBIT -25.82
VNDA's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. VNDA: -25.82 )
Ranked among companies with meaningful EV-to-EBIT only.
VNDA' s EV-to-EBIT Range Over the Past 10 Years
Min: -1288.6  Med: -1 Max: 578.2
Current: -25.82
-1288.6
578.2
EV-to-EBITDA -71.54
VNDA's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. VNDA: -71.54 )
Ranked among companies with meaningful EV-to-EBITDA only.
VNDA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -83.3  Med: -0.9 Max: 81.6
Current: -71.54
-83.3
81.6
Current Ratio 3.46
VNDA's Current Ratio is ranked lower than
56% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. VNDA: 3.46 )
Ranked among companies with meaningful Current Ratio only.
VNDA' s Current Ratio Range Over the Past 10 Years
Min: 3.25  Med: 6.46 Max: 18.2
Current: 3.46
3.25
18.2
Quick Ratio 3.45
VNDA's Quick Ratio is ranked lower than
53% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. VNDA: 3.45 )
Ranked among companies with meaningful Quick Ratio only.
VNDA' s Quick Ratio Range Over the Past 10 Years
Min: 3.22  Med: 6.46 Max: 17.54
Current: 3.45
3.22
17.54
Days Inventory 14.19
VNDA's Days Inventory is ranked higher than
89% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. VNDA: 14.19 )
Ranked among companies with meaningful Days Inventory only.
VNDA' s Days Inventory Range Over the Past 10 Years
Min: 15.31  Med: 151.44 Max: 596.04
Current: 14.19
15.31
596.04
Days Sales Outstanding 50.66
VNDA's Days Sales Outstanding is ranked higher than
59% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. VNDA: 50.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
VNDA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 5.22  Med: 24.24 Max: 253.93
Current: 50.66
5.22
253.93

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.60
VNDA's 3-Year Average Share Buyback Ratio is ranked higher than
56% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. VNDA: -9.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
VNDA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -14.9  Med: -6.35 Max: 0
Current: -9.6
-14.9
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 10.17
VNDA's Price-to-Net-Cash is ranked lower than
65% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. VNDA: 10.17 )
Ranked among companies with meaningful Price-to-Net-Cash only.
VNDA' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.31  Med: 11.23 Max: 125
Current: 10.17
0.31
125
Price-to-Net-Current-Asset-Value 6.69
VNDA's Price-to-Net-Current-Asset-Value is ranked lower than
52% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. VNDA: 6.69 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
VNDA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.3  Med: 10.51 Max: 185
Current: 6.69
0.3
185
Price-to-Tangible-Book 6.14
VNDA's Price-to-Tangible-Book is ranked lower than
61% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. VNDA: 6.14 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
VNDA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.29  Med: 6.77 Max: 31.09
Current: 6.14
0.29
31.09
Price-to-Median-PS-Value 0.73
VNDA's Price-to-Median-PS-Value is ranked higher than
70% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. VNDA: 0.73 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
VNDA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.55  Med: 1.05 Max: 11.48
Current: 0.73
0.55
11.48
Earnings Yield (Greenblatt) % -3.87
VNDA's Earnings Yield (Greenblatt) % is ranked higher than
57% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. VNDA: -3.87 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
VNDA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.2  Med: 34.4 Max: 3521.3
Current: -3.87
0.2
3521.3

More Statistics

Revenue (TTM) (Mil) $146.0
EPS (TTM) $ -0.42
Beta0.97
Short Percentage of Float6.45%
52-Week Range $8.04 - 18.00
Shares Outstanding (Mil)44.35

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 169 195 223
EPS ($) -0.48 -0.09 0.34
EPS without NRI ($) -0.48 -0.09 0.34
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for VNDA

Headlines

Articles On GuruFocus.com
Vanda Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 2, 2017 Apr 13 2017 
Vanda and UCSF Announce License Agreement for CFTR Activators and Inhibitors Mar 31 2017 
Weekly CEO Sells Highlight: Cameron International, Envision Healthcare Holdings, Vanda Pharmaceutica Sep 20 2015 
Weekly CEO Sells Highlight: Walker & Dunlop, Arista Networks, Vanda Pharmaceuticals, and Synopsys May 31 2015 
John Paulson's Stocks Trading for Less Than He Paid for Them Jun 02 2014 
Best Performing Gurus of Past Six Months are John Paulson, First Eagle and Michael Price Jun 11 2013 
Vanda: This Company Has Great Assets But No Profits Jan 21 2012 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 10 2011 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-Q) May 10 2010 

More From Other Websites
Vanda Pharmaceuticals, Inc. – Value Analysis (NASDAQ:VNDA) : April 20, 2017 Apr 20 2017
Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : April... Apr 19 2017
Vanda Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 2, 2017 Apr 13 2017
Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : March... Mar 31 2017
Vanda and UCSF Announce License Agreement for CFTR Activators and Inhibitors Mar 29 2017
Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : March... Mar 07 2017
Vanda Pharmaceuticals Announces Participation at March 2017 Investor Conferences Mar 06 2017
Vanda Pharmaceuticals, Inc. :VNDA-US: Earnings Analysis: Q4, 2016 By the Numbers : February 22, 2017 Feb 22 2017
Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US :... Feb 21 2017
Edited Transcript of VNDA earnings conference call or presentation 15-Feb-17 9:30pm GMT Feb 15 2017
Vanda reports 4Q loss Feb 15 2017
Vanda Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results Feb 15 2017
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2016 Financial Results on February... Jan 19 2017
Merck KGaA Expands Distribution Deal with Roche (revised) Jan 17 2017
D.C.-area biotech stocks fall on Trump's tough talk on industry Jan 11 2017
Jefferies Has 5 Top Biotech Stocks to Buy for 2017 Jan 10 2017
Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2016 Revenue Results and 2017... Jan 09 2017
Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US :... Jan 02 2017
Abbott Labs to Close St. Jude Acquisition Later this Week Jan 02 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)